Sharp receives MHRA approval for Clinical Services Centre of Excellence

RHYMNEY, WALES, UNITED KINGDOM - Apr 15, 2019 - Sharp - part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has received approval from the Medicines and Healthcare Product Regulatory Agency (MHRA) to begin production at its Clinical Services Centre of Excellence in Rhymney, Wales.

Following a successful inspection by the MHRA, Sharp can now offer a range of clinical trial and commercial services from the £9.5 million facility including primary and secondary packaging with low humidity control, labelling, storage and distribution, QP services as well as controlled drug storage.

The Centre also enables Sharp to offer a broader range of integrated services including serialisation and Interactive Response Technology (IRT) solutions for clinical trial management.

Frank Lis, president of Sharp Clinical Services, said: “The Clinical Services Centre of Excellence in Rhymney has tripled Sharp’s clinical service capacity for the pharmaceutical, biotech and clinical research sectors.

“With the integrated capabilities on offer, the facility also better enables us to offer full-service support and meet the increased global demand for Phase III clinical trials and commercial pharmaceutical services.

“We are dedicated to supporting our customers for years to come and the Rhymney site is a sign of that commitment.”

The MHRA approval comes as Sharp celebrates its 30th year of clinical operations in the UK.

Lis added: “To be able to celebrate two such significant achievements at the same time is testament to the effort and dedication of everyone involved in the success of Sharp.”

Sharp has also invested in a solar panel system at the site that will generate approximately 20% of Sharp Clinical Services’ total annual electricity requirements, further reducing the company’s carbon footprint and increasing environmental performance.